statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Latest Ratings for OCGN
 DateFirmActionFromTo Feb 2022HC Wainwright & Co.MaintainsBuy Jun 2021Roth CapitalDowngradesBuyNeutral Jun 2021HC Wainwright & Co.MaintainsBuy
 View More Analyst Ratings...

Key Takeaways From Ocugen Analyst Ratings

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGN SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen...

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGN

OCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ocugen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! OCGN INVESTOR ALERT: Bronstein...

OCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ocugen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen PR...

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen

ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN ROSEN, THE FIRST FILING FIRM...

ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc...

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc...

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm

Law Offices of Howard G. Smith announces an investigation on behalf of Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN) investors concerning the Companys possible violations of federal securities...

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Ocugen, Inc. (OCGN) on Behalf of Investors

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ocugen, Inc. - OCGN SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ocugen...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ocugen, Inc. - OCGN

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen PR Newswire NEW...

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Volume	4.00
52-Wk High	$2.11
52-Wk Low	$0.345

OCGN Ocugen Inc

About

Feed

News

Sentiment

Earnings

Fundamentals